Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 23 ... A report, 'Depression, cortisol, and suppressed cell-mediated immunity in metastatic breast cancer,' is newly published data in Brain, Behavior, and Immunity. "Cancer treatment ... patients may be particularly susceptible. CMI is also important for defense against some tumors. This study explored relationships among depressive symptoms, cortisol secretion, and ...
2009 NOV 23 ... researchers concluded: "Our growing understanding of the actions of glucocorticoids on breast tumors could lead to important changes in cancer treatment." Trainor and ...
2009 NOV 23 ... are used in the treatment of a number of solid tumors, including colorectal, breast, gastric, pancreatic, prostate, and bladder cancers." "Common side ...
2009 NOV 23 ... (atypical ductal hyperplasia and/or ductal carcinoma in situ) and invasive ductal breast carcinoma from 52 patients, together with pure lesions from 24 patients and 12 normal ... in methylation levels or frequencies, CDH1 showed higher methylation levels in invasive tumors as compared with preinvasive lesions (P < 0.04, Mann-Whitney test with permutation ...
2009 NOV 23 ... (TIMP-1 and TIMP-2) in tumor samples obtained from patients with primary breast cancer. We attempted to correlate these findings with the status of the sentinel lymph ... cancer were analyzed. The immunoreactivity of VEGF, MMP-2, MMP-9, TIMP-1, and TIMP-2 in tumors was correlated with clinical and pathological features, as well as SLN status. ...
2009 NOV 23 ... of radiotherapy resistance: a possible role for the 26S proteasome' new findings in breast cancer. "We aimed to identify putative predictive protein biomarkers of ... expression of this target was also found to be associated with radioresistant laryngeal tumors (p=.05) in a small pilot immunohistochemical study," wrote L. Smith and colleagues, ...
2009 NOV 23 ... Research findings, 'The alternative lengthening of telomeres phenotype in breast carcinoma is associated with HER-2 overexpression,' are discussed in a new report. ... telomeres (ALT). The ALT phenotype, relatively common in certain sarcomas and germ cell tumors, is very rare in carcinomas," scientists in the United States report. "In ...
2009 NOV 23 ... P2rx7(-/-) or Nlrp3(-/-) or Casp1(-/-) hosts. Anthracycline-treated individuals with breast cancer carrying a loss-of-function allele of P2RX7 developed metastatic disease more ... is provided. Accordingly, anticancer chemotherapy turned out to be inefficient against tumors established in purinergic receptor P2rx7(-/-) or Nlrp3(-/-) or Casp1(-/-) hosts. ...
2009 NOV 23 ... "Sentinel lymph node (SLN) surgery is widely used for nodal staging in early-stage breast cancer This study was pet-formed to evaluate the accuracy of SLN surgery for patients ... patients were younger (51 vs. 57 years, P< 0.0001) and had more clinical T2-T3 tumors (87.3% vs 18.8%, P< 0.0001) at diagnosts SLN identification rates were 97.4% in the ...
2009 NOV 23 ... "Given their frequent expression in breast and gynecologic carcinomas, the National Comprehensive Cancer Network has recommended ... tissue microarray sections representing 348 nonbreast or gynecologic and nongynecologic tumors of lung, esophageal, gastric, pancreatic, colonic, renal, or bladder origin. We also ...
2009 NOV 23 ... of the human epidermal growth factor receptor 2 (HER2) is amplified in 25% to 30% of breast cancers and has been associated with an unfavorable prognosis. Here we report the ... that Affitoxin is an attractive PE38-based candidate for treatment of HER2-positive tumors." Zielinski and colleagues published their study in the Journal of ...
2009 NOV 23 ... United States conducted a study "To assess the feasibility of percutaneous multiprobe breast cryoablation (BC) for diverse presentations of cancers that remained in situ after BC. ... for up to 72 months after BC. US produced sufficient ice visualization for small tumors, whereas CT helped confirm overall ice extent. The mean pretreatment breast tumor ...
2009 NOV 23 ... studies have shown that dietary flaxseed (FS) can reduce the growth of established human breast tumors in athymic mice with low circulating estrogen concentrations, In this study, we ...
2009 NOV 23 ... "Scintimammography is an imaging tool for the diagnosis and management of primary breast tumors. There remains a significant knowledge gap regarding the physiological fluctuations in ...
2009 NOV 23 ... GlaxoSmithKline/Nippon Kayaku's Tykerb/Tyverb -- were the highest-selling drug class in breast cancer treatment. Continued uptake of Herceptin and Tykerb/Tyverb and the expected ... The PARP inhibitors represent a novel therapeutic strategy in DNA-repair-deficient tumors, such as triple-negative breast cancer. "PARP inhibitors, which include ...
2009 NOV 23 ... USA. Keywords: Country:Italy, Aromatase, Breast Cancer, Breast Carcinoma, Breast Tumors, Drugs, Enzymes, Estradiol, Kinase, Molecular Endocrinology, Mutagenesis, Oncology, ...
2009 NOV 23 ... Biomedical Engineering, Biomedicine, Biotechnology, Breast Cancer, Breast Carcinoma, Breast Tumors, Oncology, Tissue Engineering, Women's Health, Duke University. This ...
2009 NOV 23 ... worse than the relative cumulative survival of patients with all other invasive breast tumors during the same time period. Squamous cell carcinoma of the breast is a rare and ...
2009 NOV 23 ... Larry Norton. The Company expects to initiate a Phase I/II study of oral indibulin in breast cancer patients employing this dosing schedule established preclinically. Once the ... toxicity. Phase I and Phase II testing of the intravenous form of darinaparsin in solid tumors and hematological cancers has been completed or is nearing completion. The Company has ...
2009 NOV 23 ... Oral indibulin (ZybulinTM or ZIO-301) is scheduled to enter into a Phase I/II study in breast cancer patients using the Norton-dosing schedule developed preclinically with Dr. Larry ... toxicity. Phase I and Phase II testing of the intravenous form of darinaparsin in solid tumors and hematological cancers has been completed or is nearing completion. The Company has ...
